SABCS 2025 – Gilead hasn’t given up on its Ascent
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
ESMO 2025 – Lilly strengthens Verzenio’s case
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
Vepdegestrant’s promise narrows
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
Will Roche's Perseverance pay off?
Giredestrant will soon become the first oral SERD to yield first-line data.
Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
KAT6 catalysts to kick off 2025
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
